Abstract:Our previous studies showed that cysteinyl leukotriene receptor-1 (CysLT(1)) antagonist pranlukast has a neuroprotective effect on cerebral ischemia in rats and mice. However, whether the neuroprotective effect of pranlukast is its special action or a common action of CysLT1 receptor antagonists remains to be clarified. This study was performed to determine whether montelukast, another CysLT1 receptor antagonist, has the neuroprotective effect on focal cerebral ischemia in mice, and to observe its dose- and time-dependent properties. Permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO). Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls. The neurological deficits, infarct volumes, brain edema, neuron density, and Evans blue extravasation in the brain were determined 24 h after MCAO. Pretreatments with multiple doses or a single dose of montelukast (0.1 and 1.0 mg/kg) before MCAO significantly attenuated all the ischemic insults. Post-treatment with a single dose of montelukast (0.1 and 1.0 mg/kg) at 30 min after MCAO also significantly decreased brain edema and infarct volume, but not neurological deficits. However, post-treatment with a single dose of montelukast at 1 h after MCAO had no significant effect. Pranlukast showed the same effects as montelukast, but edaravone attenuated the ischemic insults only with multiple doses before MCAO. Thus, montelukast has a dose- and time-dependent neuroprotective effect on permanent focal cerebral ischemia in mice, with an effective dose range of 0.1-1.0 mg/kg and a therapeutic window of 30 min. These findings further support the therapeutic potential of CysLT(1) receptor antagonists in the treatment of cerebral ischemia at earlier phases. Copyright (C) 2005 S. Karger AG, Basel.

Protective Effect Of Pranlukast On A Beta(1-42)-Induced Cognitive Deficits Associated With Downregulation Of Cysteinyl Leukotriene Receptor 1

Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo

Preventive Effect of Genetic Knockdown and Pharmacological Blockade of CysLT1R on Lipopolysaccharide (Lps)-Induced Memory Deficit and Neurotoxicity in Vivo

Montelukast Targeting the Cysteinyl Leukotriene Receptor 1 Ameliorates Aβ1-42-induced Memory Impairment and Neuroinflammatory and Apoptotic Responses in Mice

Leukotriene D4 Induces Cognitive Impairment Through Enhancement of CysLT1R-mediated Amyloid-Β Generation in Mice

CysLT1R Downregulation Reverses Intracerebroventricular Streptozotocin-Induced Memory Impairment Via Modulation of Neuroinflammation in Mice

Pranlukast, a Cysteinyl Leukotriene Receptor-1 Antagonist, Protects Against Chronic Ischemic Brain Injury and Inhibits the Glial Scar Formation in Mice

Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ 1-42-induced memory impairment and neurotoxicity in mice.

Pranlukast Reduces Neutrophil but Not Macrophage/microglial Accumulation in Brain after Focal Cerebral Ischemia in Mice

Effects of Pranlukast on Scopolamine-induced Memory Impairment in Mice

Montelukast Ameliorates Streptozotocin-Induced Cognitive Impairment and Neurotoxicity in Mice.

Effect of pranlukast on memory impairment and nerve injury in streptozocin-induced type 1 diabetic mice

Pranlukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Protects Mice Against Brain Cold Injury

Therapeutic Effect of Pranlukast, a Cysteinyl Leukotriene Receptor Antagoist, on Focal Cerebral Ischemia in Mice

Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.

Pranlukast Dose-and Time-Dependently Protects Against Ischemic Neuronal Damage in the Rat Hippocampus

Montelukast, A Cysteinyl Leukotriene Receptor-1 Antagonist, Attenuates Chronic Brain Injury after Focal Cerebral Ischaemia in Mice and Rats

S -Propargyl-cysteine (ZYZ-802), a Sulphur-Containing Amino Acid, Attenuates Beta-Amyloid-induced Cognitive Deficits and Pro-Inflammatory Response: Involvement of ERK1/2 and NF-κB Pathway in Rats

Protective Effect of Z-ligustilide Against Amyloid Β-Induced Neurotoxicity is Associated with Decreased Pro-Inflammatory Markers in Rat Brains

Protective Effect of N-acetyl-l-cysteine on Amyloid Β-Peptide-induced Learning and Memory Deficits in Mice

Plasminogen decreases Aβ42 and Tau deposition, and shows multi-beneficial effects on Alzheimer's disease in mice and humans